Zytiga (abiraterone acetate) is a prescription drug used in combination with prednisone to treat men with metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting CYP17, an enzyme involved in testosterone production, thereby reducing androgen levels that fuel prostate cancer growth. Zytiga is taken orally once daily on an empty stomach to maximize absorption. Patients must use it under close medical supervision due to potential side effects such as high blood pressure, low potassium levels, liver function abnormalities, and fluid retention. Regular monitoring by healthcare providers is essential during treatment.